Ophthalmology
Lucentis approved for diabetic retinopathy
(HealthDay)—A drug to treat the most common eye disease among diabetics has been approved by the U.S. Food and Drug Administration.
Feb 9, 2015
0
5
News tagged with lucentis
Medications
FDA approves Regeneron's eye injection Eylea
(AP) -- Regulators on Friday approved Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat a common cause of blindness in older people.
Nov 19, 2011
5
0
Diseases, Conditions, Syndromes
Study finds Avastin and Lucentis are equally effective in treating AMD
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is ...
Apr 28, 2011
0
0
Ophthalmology
New drug could help AMD sufferers
There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected ...
Jun 18, 2013
0
0
Diseases, Conditions, Syndromes
Mayo Clinic detective work shows possible side effect in macular degeneration drug
Two major drug trials conclude there was little risk from a drug aimed at age-related macular degeneration. Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure ...
Oct 24, 2011
0
1
Ophthalmology
Avastin and Lucentis are equivalent in treating age-related macular degeneration
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although ...
Apr 30, 2012
1
0
Ophthalmology
Avastin has similar effect to Lucentis in treating wet age-related macular degeneration
The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported today at an international ...
May 7, 2012
0
0
Ophthalmology
Major clinical trial finds no link between genetic risk factors and 2 top wet AMD treatments
New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts ...
Feb 12, 2013
0
0
Medications
Novartis tries to make UK hospitals use $1000 drug
(AP) -- Drug maker Novartis says it is taking legal action in Britain to make hospitals use an eye drug that costs 700 pounds ($1,130) per shot instead of a cheaper one that costs 60 pounds ($97).
Apr 24, 2012
0
0
Diseases, Conditions, Syndromes
Cheaper anti-cancer drug as effective as expensive drug in treating most common cause of blindness in older adults
An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.
Jul 19, 2013
0
0
Ranibizumab
Ranibizumab (trade name Lucentis) is a monoclonal antibody fragment (Fab) derived from the same parent mouse antibody as bevacizumab (Avastin). It is much smaller than the parent molecule and has been affinity matured to provide stronger binding to VEGF-A. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (ARMD), a common form of age-related vision loss.
Some investigators believe that bevacizumab at an average cost of $42 a dose (in the U.S.) is as effective as ranibizumab at an average cost of $1,593 a dose.
Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis.
This text uses material from Wikipedia, licensed under CC BY-SA
